AstraZeneca and MSD launch prostate cancer awareness campaign
AstraZeneca and MSD (known as Merck & Co. in the US and Canada) have announced their collaborative global prostate cancer awareness campaign. The campaign, called Never Miss, has the slogan: “Never miss a game. Never miss a goal. Never miss a chance at early diagnosis.”, which aims to open up conversations about prostate cancer as well as helping men understand the risk of the disease.
With prostate cancer ranked as the second most common cancer in men globally, it is hugely significant to spread awareness. Often the disease shows no symptoms or symptoms that develop very slowly, so it is often not detected early. In 2020, there were 1.4 million new cases and 375,000 deaths globally.
The Never Miss campaign has been developed to tackle the prediction that prostate cancer mortality is likely to double in the next 20 years.
Sunil Verma, AstraZeneca’s global head of oncology medical, commented: “Our top priority in breaking down barriers to prostate cancer awareness and detection is always to listen to the community affected by this disease, act on these insights and ensure the patient voice is heard.”
Sophie Opdyke, Merck ’s senior vice president of global oncology marketing, added: “We know that when prostate cancer is detected early, the outcomes for patients may be greatly improved. Through the ‘Never Miss’ campaign, we hope to raise awareness of risk factors for prostate cancer, break down social barriers and empower men to take control of their health.”
Pharmaceutical Industry news, analysis and insights